109 filings
8-K
RCKT
Rocket Pharmaceuticals Inc
6 May 24
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
5:26pm
8-K
RCKT
Rocket Pharmaceuticals Inc
29 Mar 24
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
5:17pm
8-K
RCKT
Rocket Pharmaceuticals Inc
26 Feb 24
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
4:37pm
8-K
RCKT
Rocket Pharmaceuticals Inc
13 Feb 24
Other Events
4:37pm
8-K
RCKT
Rocket Pharmaceuticals Inc
13 Dec 23
Departure of Directors or Certain Officers
4:05pm
8-K
jghz7pkf
2 Oct 23
Other Events
4:05pm
8-K
fihclbwqs4v9jp41
15 Sep 23
Entry into a Material Definitive Agreement
4:01pm
8-K
7ro49ijf9ww1iwqtrza
12 Sep 23
Entry into a Material Definitive Agreement
9:53pm
8-K
jcp5 yukn5c
12 Sep 23
Regulation FD Disclosure
4:53pm
8-K
6vhcsrmvwbjzn1cdijxz
23 Jun 23
Submission of Matters to a Vote of Security Holders
4:27pm
8-K
33m mkka5g
4 Apr 23
Departure of Directors or Certain Officers
5:14pm
8-K
o3qm503gwgpq1 7jozl
10 Mar 23
Regulation FD Disclosure
11:59am
8-K
vvt66
27 Feb 23
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
5:22pm
8-K
0y5sf60c5x cx
7 Feb 23
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
4:50pm
8-K
5utsfo
9 Jan 23
Other Events
4:29pm
8-K
fatda
22 Dec 22
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease
4:06pm
8-K
zfsp9x hqktkqib0mn
1 Dec 22
Rocket Pharmaceuticals Completes Acquisition of Renovacor
4:31pm
8-K
ddbubph2
3 Nov 22
Results of Operations and Financial Condition
5:10pm
8-K
tvzv6jx 9sucwy6q
4 Oct 22
Entry into a Material Definitive Agreement
5:28pm
8-K
fu50j0 mhtdp
3 Oct 22
Other Events
4:38pm